Anaplastic thyroid cancer (ATC), a rare yet highly aggressive malignancy, continues to represent a major clinical challenge.

A new wave of scientific interest is spotlighting GOT2—glutamic-oxaloacetic transaminase 2—as a compelling therapeutic target in the fight against ...